Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2. Our scientists are simultaneously reviewing known pathways in coronavirus pathophysiology to determine whether previously tested medicines can be used to help patients survive COVID-19 and reduce the severity of disease in non-lethal cases.
